On September 13, 2021 2seventy bio, the planned oncology spin-off of bluebird bio (NASDAQ: BLUE) reported that it will host a series of investor events to share further detail on its research pipeline and strategy (Press release, bluebird bio, SEP 13, 2021, View Source [SID1234587672]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Session One: An Introduction to 2seventy’s Pipeline; focus on AML [DARIC33] and Next-Gen Multiple Myeloma Strategy
September 21, 2021, 11:00am-12:00pm ET
Session Two: Focus on bNHL [bbT369] and Solid Tumor Strategy
September 22, 2021, 1:00-2:00pm ET
To access the live webcasts and dial-in information for 2seventy bio’s presentations, please visit the "Events & Presentations" page within the Investors & Media section of the bluebird bio website at View Source Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.